Journal of Skin and Stem Cell

Published by: Kowsar

Calcipotriol Plus Betamethasone Versus Betamethasone in Treatment of Scalp Psoriasis in an Iranian Population

Abbas Zamanian 1 , Zahra Azizian 2 , * , Zahra Mehrnahad 2 and Golnaz Mehran 3
Authors Information
1 Associate Professor of Dermatology, Rasoul-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
2 Dermatologist, Rasoul-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
3 Assistant Professor of Dermatology, Rasoul-Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
Article information
  • Journal of Skin and Stem Cell: June 2016, 3 (2); e62117
  • Published Online: June 30, 2016
  • Article Type: Research Article
  • Received: May 3, 2016
  • Revised: May 22, 2016
  • Accepted: June 18, 2016
  • DOI: 10.5812/jssc.62117

To Cite: Zamanian A, Azizian Z, Mehrnahad Z, Mehran G. Calcipotriol Plus Betamethasone Versus Betamethasone in Treatment of Scalp Psoriasis in an Iranian Population, J Skin Stem Cell. 2016 ;3(2):e62117. doi: 10.5812/jssc.62117.

Copyright: Copyright © 2016, Journal of Skin and Stem Cell. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Girolomoni G, Vena GA, Ayala F, Cannavo SP, De Pita O, Chimenti S, et al. Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. G Ital Dermatol Venereol. 2012;147(6):609-24. [PubMed: 23149707].
  • 2. McCormack PL. Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp. Drugs. 2011;71(6):709-30. doi: 10.2165/11207300-000000000-00000. [PubMed: 21504248].
  • 3. Fleming C, Ganslandt C, Guenther L, Johannesson A, Buckley C, Simon JC, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol. 2010;20(4):465-71. doi: 10.1684/ejd.2010.0948. [PubMed: 20413372].
  • 4. Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59(3):455-63. doi: 10.1016/j.jaad.2008.04.027. [PubMed: 18694678].
  • 5. Tyring S, Mendoza N, Appell M, Bibby A, Foster R, Hamilton T, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol. 2010;49(11):1328-33. doi: 10.1111/j.1365-4632.2010.04598.x. [PubMed: 20964660].
  • 6. Tremezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going?. Dermatoendocrinol. 2011;3(3):180-6. doi: 10.4161/derm.3.3.17534. [PubMed: 22110777].
  • 7. Raychaudhuri S, Mitra A, Datta-Mitra A. Immunomodulatory mechanisms of action of calcitriol in psoriasis. Indian J Dermatol. 2014;59(2):116-22. doi: 10.4103/0019-5154.127668. [PubMed: 24700927].
  • 8. King EM, Chivers JE, Rider CF, Minnich A, Giembycz MA, Newton R. Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms. PLoS One. 2013;8(1):53936. doi: 10.1371/journal.pone.0053936. [PubMed: 23349769].
  • 9. Tran NP, Vickery J, Blaiss MS. Management of rhinitis: allergic and non-allergic. Allergy Asthma Immunol Res. 2011;3(3):148-56. doi: 10.4168/aair.2011.3.3.148. [PubMed: 21738880].
  • 10. Krikun G, Lockwood CJ. Steroid hormones, endometrial gene regulation and the Sp1 family of proteins. J Soc Gynecol Investig. 2002;9(6):329-34. [PubMed: 12445596].
  • 11. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335(1):2-13. doi: 10.1016/j.mce.2010.04.005. [PubMed: 20398732].
  • 12. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23-31. doi: 10.3109/09546634.2013.865009. [PubMed: 24354461].
  • 13. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-43. doi: 10.1038/jid.2009.391. [PubMed: 20043014].
  • 14. Garcia-Perez ME, Stevanovic T, Poubelle PE. New therapies under development for psoriasis treatment. Curr Opin Pediatr. 2013;25(4):480-7. doi: 10.1097/MOP.0b013e328362c3f6. [PubMed: 23838833].
  • 15. Pfohler C, Muller CS, Vogt T. Psoriasis vulgaris and psoriasis pustulosa - epidemiology, quality of life, comorbidities and treatment. Curr Rheumatol Rev. 2013;9(1):2-7. [PubMed: 25139811].
  • 16. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci. 2012;1261:55-63. doi: 10.1111/j.1749-6632.2012.06633.x. [PubMed: 22823394].
  • 17. Papp KA, Guenther L, Boyden B, Larsen FG, Harvima RJ, Guilhou JJ, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol. 2003;48(1):48-54. doi: 10.1067/mjd.2003.130. [PubMed: 12522370].
  • 18. Tadicherla S, Ross K, Shenefelt PD, Fenske NA. Topical corticosteroids in dermatology. J Drugs Dermatol. 2009;8(12):1093-105. [PubMed: 20027937].
  • 19. Abraham A, Roga G. Topical steroid-damaged skin. Indian J Dermatol. 2014;59(5):456-9. doi: 10.4103/0019-5154.139872. [PubMed: 25284849].
  • 20. Sun J, Dou W, Zhao Y, Hu J. A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model. Immunopharmacol Immunotoxicol. 2014;36(1):17-24. doi: 10.3109/08923973.2013.862542. [PubMed: 24286371].
  • 21. Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi: 10.1155/2012/561018. [PubMed: 23213332].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader